T-WAVE may be a worthwhile option for your adolescent and adult patients with absence seizures who meet the study criteria and are not satisfied with currently available treatment options.
T-WAVE (clinicaltrials.gov) is an open-label Phase 2a clinical trial that will assess the safety, tolerability, pharmacokinetics and quantitative EEG of investigational oral drug CX-8998 in adolescents and adults diagnosed with idiopathic genetic epilepsy syndrome (IGE) with absence seizures. The study will also explore whether CX-8998 decreases the frequency and duration of absence seizures by targeting calcium channels in the brain’s neural network to reduce abnormal activity. Calcium and ion channels play a critical role in neuronal signaling. The T-type calcium channel, Cav3, mediates the transition to burst-firing and abnormal oscillatory patterns in a number of neurologic disorders, including epilepsy. CX-8998 may restore the brain’s natural rhythms via modulation of overactive T-type calcium channels.
T-WAVE is being conducted with up to 15 participants at several medical research sites in the Midwest and East Coast. Subjects will enter a screening period of up to four weeks and participate in a four-week dose titration treatment period followed by a one-week safety follow-up period after the last dose of study medication. You can also refer patient candidates to our study sites for more information.
CX-8998 is an oral drug being developed by Cavion that was designed to restore the brain’s natural rhythms by modulating overactive T-type calcium channels.
Calcium and ion channels play a critical role in neuronal signaling. The T-type calcium channel Cav 3 mediates the transition from tonic to bust-firing and generates neural “oscillations” between brain nuclei and across neural networks. Cav 3 mediates the transition to burst-firing and abnormal oscillatory patterns in a number of neurologic disorders, including epilepsy, essential tremor, Parkinson’s disease, dystonia, pain, and schizophrenia. CX-8998 is a potential best-in-class T-type calcium channel modulator with superior potency and selectivity as well as a favorable safety and tolerability profile.
CX-8998 has been studied in nearly 250 people, mostly healthy volunteers and some people with other neurological conditions.
Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.
Hum Psychopharmacol. 2013 Mar;28(2):124-33. doi: 10.1002/hup.2289.